AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03009474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CJ-30060
Description: Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg
Study NCT03009474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exforge tab 5/160mg, Crestor tab 10mg
Description: Co-administration of Amlodipine 5 mg/ Valsartan 160 mg(combination drug) and Rosuvastatin 10 mg
Study NCT00763126 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stress level
Description: Stress levels
Study NCT01013207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Pre Nexus (S9)
Description: This is the patient's own CPAP prior to trialling the Nexus (S9). 4 weeks of data will be downloaded from this device and compared to 4 weeks using Nexus (S9), and 4 weeks usage post trialling Nexus (S9)
Study NCT01013207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexus (S9)
Description: The patient will use the new Nexus (S9) CPAP for four weeks in place of their usual CPAP every night when they sleep to treat their OSA. Compliance data will be compared between four weeks on this device to the last four weeks on their current device (CPAP Pre S9). After using the Nexus (S9) CPAP for four weeks, participants will return to their current device for four weeks. Data from this post-trial period will be compared with both the Nexus (S9) four weeks, and the four weeks pre Nexus (S9) usage.
Study NCT01013207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Post Nexus (S9)
Description: After trialling the Nexus (S9) for four weeks, patients will return to their usual CPAP. Data from the patient's usual CPAP for four weeks will be compared to data while using the Nexus (S9), and data from the patient's usual device pre trialling S9 (CPAP Pre Nexus)
Study NCT04260789 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Seraph 100,The Microbind Affinity Blood Filter
Description: Treatment with Seraph 100 in one arm
Study NCT00900328 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative Studies
Study NCT01866605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intravenous midazolam 0.3 mg/kg
Study NCT01866605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline injection will be given to groups not receiving midazolam
Study NCT01866605 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bair Hugger
Description: Forced air warming
Study NCT02874235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receptive music therapy
Description: 16 sessions of a length of one hour comprising of receptive music psychotherapy with 5 - 15 minutes of music listening included
Study NCT02874235 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological treatment
Description: 16 sessions of a length of one hour comprising of verbal based psychotherapy based on principles from Narrative Exposure Therapy or Cognitive Behavioral Therapies
Study NCT04352075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous biologic drug of innovative therapy /cell therapy drug
Description: Articular knee injection of microfat associated with a dose of 3 billions of platelets or associated with a dose of 1 billion of platelets or with saline solution
Study NCT02333175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialist review
Description: Specialist review with individually tailored treatment strategies suggested by specialist
Study NCT03432130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural training program
Description: 15-week experimental structural training protocol
Study NCT01331525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.
Study NCT04141566 — intervention group
Intervention type: PROCEDURE
Intervention: Perineal pseudocontinent colostomy
Description: The procedure is performed in 2stages: as a usual APR starting by a laparoscopic approach esnsuring a complete mesorectal excision,then a perineal approach ensuring an extended excision of the entire internal and external sphincter complex, allowing the excision of the specimen.~8to10cm of tof the colon is resected and harvested as a free graft, stripped of its meso and epiploics , then from its mucosa and placed in an antibiotic solution for 10min. This graft is wrapped snugly around the end of the colon 2-3 cm from its distal end for 1 and a half round. Absorbable 3.0 Sutures are taken to hold it in place. The end of the colon is brought out as a stoma in the perineum.~Colonic irrigations are started from the third day according to the protocol previously reported. Patients and one of their family members are daily educated and assisted while performing colonic irrigations by specialized nurses.
Study NCT04141566 — intervention group
Intervention type: PROCEDURE
Intervention: Permanent left iliac colostomy
Description: After a usual laparoscopic APR, the perineal wound is closed and a permanent left iliac colostomy is performed
Study NCT01387958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Study NCT01387958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02525575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Life Force Group Treatment
Description: PLF, a 12-session, group psychotherapy intervention, combines Dialectical Behavioral Therapy (DBT) skill based and psychoeducational approaches, to enhance suicide safety planning development and implementation. Veterans revise their plans over several weeks while learning distress tolerance, emotion regulation, and friendship building/interpersonal skills to incorporate into their safety plans and also receive lessons on gun safety and minimizing access to lethal means. Sessions are augmented with 1) training in the use of a suicide safety planning mobile App to promote accessibility and maximize implementation, and 2) didactic information to bolster recovery, including fostering improved connection with the treatment team, and Veteran's family. Importantly, the group format mitigates loneliness and fosters increased belongingness, both key risk factors for suicide.
Study NCT02736331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 1
Description: Treatment 1 Beverage
Study NCT02736331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Treatment 2
Description: Treatment 2 Beverage
Study NCT00594958 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC51
Description: 6 mcg, intramuscularly \[i.m.\], 0.5 mL
Study NCT00004893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Study NCT00570310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: pregabalin
Description: pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
Study NCT00570310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
Study NCT01372566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harvest PRP Separation System
Description: Platelet-rich plasma (PRP) is a blood-derived therapy that consists of platelets and growth factors. PRP can be formed by drawing blood from a vein and spinning it at a high speed in a specialized device called a centrifuge.
Study NCT01372566 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline injection
Description: Sterile Saline will be injected multiple times in a different area of the arm (Part 1) or on the opposite side of the face from where the platelet rich plasma is injected.
Study NCT02741596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930
Description: Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
Study NCT02741596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930
Description: Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
Study NCT03329846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: specified dose on specified day
Study NCT03329846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day
Study NCT03329846 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified day
Study NCT03329846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified day
Study NCT04583995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix M1-Adjuvant
Description: Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.
Study NCT04583995 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
Study NCT04583995 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Licensed seasonal influenza vaccine
Description: Single intramuscular injection of licensed seasonal flu vaccine, administered ideally in opposite deltoid to SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo injection on Day 0.
Study NCT04583995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed seasonal influenza vaccine
Description: Single intramuscular injection of licensed seasonal flu vaccine, administered ideally in opposite deltoid to SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo injection on Day 0.
Study NCT01946217 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02768779 — intervention group
Intervention type: OTHER
Intervention: Hair analysis
Description: Within the laboratory, experimental factors controlling IR-MALDESI response to key ARVs representing various drug classes will be systematically evaluated using the design of experiments (DOE) statistical approach (41,127) for an unbiased optimization of IRMALDESI response to each of the ARVs and their major metabolites. The goal will be to achieve a lower limit of quantification (LLOQ) below clinically relevant hair strand concentrations.
Study NCT01817023 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SIB-IMRT
Description: SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
Study NCT01817023 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Description: SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
Study NCT01817023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 100mg/m2 was delivered at d1,d22 and d43 to the CCRT group patients during radiotherapy.
Study NCT02282280 — intervention group
Intervention type: DRUG
Intervention: Prilocaine Chlorhydrate
Description: Use of prilocaine in spinal anesthesia
Study NCT01588782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1: Abiraterone
Description: 1000 mg abiraterone acetate tablet administered orally on Day 1
Study NCT01588782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2: Abiraterone/Ketoconazole
Description: 400 mg ketoconazole tablets administered orally on Days 11 to 16
Study NCT01588782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2: Abiraterone/Ketoconazole
Description: 1000 mg abiraterone acetate tablet administered orally on Day 14
Study NCT04639960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperdal
Description: Twelve weeks of treatment with a gradual increase of dosage over one week and a gradual decrease over two weeks.
Study NCT04639960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twelve weeks of placebo treatment.
Study NCT00762554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depodur
Description: Depodur 10mg given epidurally at end of cesarean section.
Study NCT00762554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depodur
Description: Depodur 10mg given epidurally at end of cesarean section after patient received spinal bupivacaine at the beginning of the case.
Study NCT00762554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Epidural fentanyl infusion started after spinal bupivacaine used for the cesarean section.
Study NCT04155606 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: microsurgery; endovascular interventions
Description: microsurgery: surgical resection of the aneurysm endovascular interventions: coiling, stenting or both
Study NCT01714310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine
Description: Titration and open label treatment from baseline visit for 12 week study.
Study NCT01714310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lisdexamfetamine
Description: Titration and open label treatment from baseline visit for 12 week study.
Study NCT01714310 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lisdexamfetamine
Description: Titration and open label treatment from baseline visit for 12 week study.
Study NCT01714310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initiated at end of study week 4 and continued to study week 12.
Study NCT01714310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: Initiated at end of study week 4 and continued to study week 12.
Study NCT00789282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multidisciplinary approach
Description: Provides an integrated, proactive approach to the management of patients with chronic diseases (ie: diabetes and sequelae) Wagner Model- care encompassed in 3 overlapping galaxies: wider community; the health care system; and the provider organization. There are 6 essential elements: community resources and policies; health care organization; patient self-management support; delivery system design; decision support; and clinical information systems.
Study NCT02613559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK001
Description: Intravitreal Injection
Study NCT00789282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multifactorial approach - for enhanced care group
Description: optimized medical management support for development of enhanced patient self management skills organized proactive follow-up chronic disease management teams
Study NCT00789282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reflects current patterns of care
Description: Continue under the care of their family physician and specialists with referral to diabetic assessment and treatment centers at the discretion of the patient and physician.~Normal manner of care: could attend diabetic self education classes and consultations regarding management of diabetes. Or, participate in other patient self management program of their choice.
Study NCT01339975 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological sample
Description: 2 blood samples of 10mL + one urine sample~* on pre-operative d-1/d, post-operative d1 and d5(+/-2),~* one month post-operative,~* at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises.
Study NCT02613247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20
Description: Intra-articular injection of 6 mL Hylan G-F 20
Study NCT02636218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 500 ml of ketamine (0.2 mg/ml) infused at 5 ug/kg/min for 4 hours.
Study NCT02636218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% NaCl
Description: 500 ml of 0.9% NaCl infused at 5 ug/kg/min for 4 hours.
Study NCT01186237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early urinary catheter removal
Description: All patients will have foley catheters removed between 0600 and midnight of post-operative day 3 (Day 0 being the day of operation).
Study NCT01110590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY60-4552 + Vardenafil
Description: Total dose given over 14 days: 5.25 mg BAY60-4552 + 140 mg Vardenafil
Study NCT01110590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY60-4552 + Vardenafil
Description: Total dose given over 14 days: 21.0 mg BAY60-4552 + 140 mg Vardenafil
Study NCT01339975 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological sample
Description: 2 blood samples of 10mL + one urine sample~* before starting the therapy~* at first therapeutic evaluation (2 or 3 months depending on the treatment chosen)~* at the end of the study or at the date of disease progression.
Study NCT01225445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: 2.5 mg daily
Study NCT01110590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY60-4552 + Vardenafil
Description: Total dose given over 14 days: 21.0 mg BAY60-4552 + 280 mg Vardenafil
Study NCT01406821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided platelet-rich-plasma (PRP) injection
Description: Blood will be drawn, and platelet-rich plasma will be injected into the tendon under ultrasound guidance.
Study NCT01406821 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound-guided dry needling
Description: Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Nothing will be injected into the tendon.
Study NCT01043796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide treated nets and wall liners
Description: Participants will be provided a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme. Households where participants reside will be fitted with insecticide treated wall liners.
Study NCT01043796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insecticide treated nets alone
Description: Participants will be provided with a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme
Study NCT01248026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buttermilk
Description: Consumption of the 2 experimental periods~1. buttermilk (45 g/d)~2. placebo (45 g/d,)
Study NCT01110590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04176250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-7371
Description: Participants will receive TBA-7371 oral suspension 100 milligram (mg) once daily (QD) for 14 days.
Study NCT04176250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-7371
Description: Participants will receive TBA-7371 oral suspension 100 mg twice daily (BID) for 14 days.
Study NCT04176250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-7371
Description: Participants will receive TBA-7371 oral suspension 200 mg QD for 14 days.
Study NCT04176250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-7371
Description: Participants will receive TBA-7371 oral suspension 100 mg three times daily (TID) for 14 days.
Study NCT04176250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-7371
Description: Participants will receive TBA-7371 oral suspension 400 mg QD for 14 days.
Study NCT04176250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRZE
Description: Participants will receive Isoniazid \[H\] / rifampicin \[R\] / pyrazinamide \[Z\] / ethambutol \[E\] (HRZE), a fixed dose combination tablet QD for 14 days, based on weight as 40-54 kilograms (kg): 3 tablets; 55-70 kg: 4 tablets and 71 kg and over: 5 tablets.
Study NCT01248026 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Buttermilk
Description: Consumption of the 2 experimental periods~1. buttermilk (45 g/d)~2. placebo (45 g/d,)
Study NCT00934206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: running / walking at 60 % heart rate reserve 4 times per week for 4 weeks
Study NCT02983019 — intervention group
Intervention type: DRUG
Intervention: Kagocel
Description: Investigators could prescribe other drugs in frame of routine clinical practice
Study NCT05429450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Three periocular injections of methotrexate at week 0, week 3 and week 6.
Study NCT05429450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Three periocular injections of triamcinolone acetonide at week 0, week 3 and week 6.
Study NCT03019276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3101
Description: Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days .